Latest Breaking News On - Ocuphire pharma - Page 1 : comparemela.com

HC Wainwright Reaffirms Buy Rating for Ocuphire Pharma (NASDAQ:OCUP)

HC Wainwright restated their buy rating on shares of Ocuphire Pharma (NASDAQ:OCUP – Free Report) in a research note released on Monday morning, Benzinga reports. The brokerage currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Ocuphire Pharma’s Q2 2024 earnings at ($0.29) EPS, Q3 2024 earnings at ($0.29) […]

George magrathOcuphire pharmaRichmond brothers incAlliance global partnersKestra private wealth servicesOcuphire pharma incVictory capital management incAcadian asset managementFree reportGet free reportAsset managementPrivate wealth servicesVictory capital managementPhentolamine ophthalmic solutionOcuphire pharma daily

Ocuphire Pharma (NASDAQ:OCUP) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Ocuphire Pharma (NASDAQ:OCUP – Free Report) in a research report released on Monday morning, Benzinga reports. The firm currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Ocuphire Pharma’s Q2 2024 earnings at ($0.29) EPS, Q3 2024 earnings at ($0.29) […]

George magrathOcuphire pharmaRichmond brothers incVanguard group incOcuphire pharma company profileAlliance global partnersKestra private wealth servicesOcuphire pharma incAcadian asset managementFree reportGet free reportPrivate wealth servicesAsset managementEmpowered fundsPhentolamine ophthalmic solutionOcuphire pharma daily

Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesYash bhardwajLas vegasOcuphire pharmaKodiak sciences brolucizumabRegenxbio inc drugRegenxbio incDelveinsight business researchDigital diagnostics incBoehringer ingelheimKodiak sciencesCompany name drugEye diseases prevalence research groupKodiak sciences drugRoute of administrationRetinopathy pipeline insight

Ocuphire Pharma (NASDAQ:OCUP) Raised to Strong-Buy at Canaccord Genuity Group

Ocuphire Pharma (NASDAQ:OCUP) Raised to Strong-Buy at Canaccord Genuity Group
etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.

George magrathOcuphire pharmaOcuphire pharma company profileSecurities exchange commissionRichmond brothers incOcuphire pharma incAcadian asset managementCanaccord genuity groupAlliance global partnersKestra private wealth servicesVictory capital management incGet free reportExchange commissionAsset managementPrivate wealth servicesVictory capital management

Ocuphire Pharma (NASDAQ:OCUP) Price Target Lowered to $18 00 at Canaccord Genuity Group

Ocuphire Pharma (NASDAQ:OCUP) Price Target Lowered to $18 00 at Canaccord Genuity Group
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

George magrathOcuphire pharmaOcuphire pharma incRichmond brothers incVictory capital management incAlliance global partnersAcadian asset managementCanaccord genuity groupKestra private wealth servicesFree reportGlobal partnersGet free reportPrivate wealth servicesCapital managementAsset managementPhentolamine ophthalmic solution